What will be GSK's stock price in 2022?
Their GSK stock forecasts range from GBX 1,500 to GBX 2,100. On average, they expect GSK's share price to reach GBX 1,820.77 in the next year. This suggests a possible upside of 4.4% from the stock's current price. View analysts' price targets for GSK or view top-rated stocks among Wall Street analysts. How has GSK's stock price performed in 2022?
How do I buy shares of GSK (GSK)?
Shares of GSK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX).
What is the consensus view on GSK plc (GSK)?
The current consensus among 21 polled investment analysts is to Hold stock in GSK plc. This rating has held steady since July, when it was unchanged from a Hold rating. Move your mouse over past Move your mouse over a quarter or year to see how estimates have changed over time.
How much money does GSK make a year?
GSK (LON:GSK) has a market capitalization of £88.68 billion and generates £36.48 billion in revenue each year. How many employees does GSK have?
See more
Is GSK a buy sell or hold?
GSK has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 3 buy ratings, 5 hold ratings, and 1 sell rating.
Is GSK a good stock to buy now?
GSK plc - Sell Its Value Score of A indicates it would be a good pick for value investors. The financial health and growth prospects of GSK, demonstrate its potential to outperform the market. It currently has a Growth Score of B.
Will GSK stock go up?
Will GSK stock go up or down? As of 18 July 2022, the outlook for the GSK share price was mixed, with some analysts predicting that the stock could gain value over the next year, while others expected it to fall.
Is GSK overvalued?
Based on the current valuation, I consider GSK overvalued to a $42/share price.
Is GSK undervalued?
GlaxoSmithKline PLC (LSE:GSK) is undervalued as it moves towards a demerger of subsidiary Haleon, according to Berenberg. The broker believes the pharmaceutical group will come back into investors' sights as the demerger begins to receive more attention.
Does GlaxoSmithKline stock pay a dividend?
How much is Gsk's dividend? GSK pays a dividend of $2.03 per share.
What will happen to GSK shares when the company splits?
Now the demerger has taken place, the total issued ordinary share capital of Haleon will mean that GSK shareholders will jointly own 54.5%, Pfizer will continue to hold 32%, GSK will hold 6% and 7.5% will be held by Scottish limited partnerships, which provide funding to GSK pensions.
Are Pfizer shares a good buy?
That RS Rating means Pfizer stock outranks 91% of all stocks in terms of performance. The pharmaceutical company's EPS Rating, a measure of profitability, is a 89 out of a best-possible 99. The EPS Rating compares a stock's recent and longer-term earnings growth against all other stocks.
Is Unilever a good stock to buy?
Unilever PLC - Sell Its Value Score of C indicates it would be a neutral pick for value investors. The financial health and growth prospects of UL, demonstrate its potential to perform inline with the market. It currently has a Growth Score of A.
Should I buy GSK stock Zacks?
The financial health and growth prospects of FSK, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Is Sanofi a good stock to buy?
High-growth visibility from chronics, strong and debt-free balance sheet, sturdy dividends, and healthy cash position are the key positives for Sanofi, hence we retain our Buy recommendation on the stock with an unchanged PT of Rs 9,250.
Is GSK a good company to work for?
Glassdoor rating: 3.9 Other GSK Glassdoor reviews spoke highly of training and development and compensation/benefits, and 76% of current employees would recommend GSK as a place to work. An impressive 85% of employees approve of GSK's CEO, Emma Walmsley - the first female CEO to run a top 10 pharmaceutical company.
What will happen to GSK shares when the company splits?
Now the demerger has taken place, the total issued ordinary share capital of Haleon will mean that GSK shareholders will jointly own 54.5%, Pfizer will continue to hold 32%, GSK will hold 6% and 7.5% will be held by Scottish limited partnerships, which provide funding to GSK pensions.
Should I buy GSK stock Zacks?
The financial health and growth prospects of FSK, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Are Pfizer shares a good buy?
That RS Rating means Pfizer stock outranks 91% of all stocks in terms of performance. The pharmaceutical company's EPS Rating, a measure of profitability, is a 89 out of a best-possible 99. The EPS Rating compares a stock's recent and longer-term earnings growth against all other stocks.
Is Unilever a good stock to buy?
Unilever PLC - Sell Its Value Score of C indicates it would be a neutral pick for value investors. The financial health and growth prospects of UL, demonstrate its potential to perform inline with the market. It currently has a Growth Score of A.
Should I buy or sell GSK stock right now?
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating,...
How has GSK's stock price performed in 2022?
GSK's stock was trading at $44.10 on January 1st, 2022. Since then, GSK stock has decreased by 0.7% and is now trading at $43.80. View the best gr...
Are investors shorting GSK?
GSK saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 6,020,000 shares, a decline of 18.1%...
When is GSK's next earnings date?
GSK is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for GSK .
How were GSK's earnings last quarter?
GSK plc (NYSE:GSK) issued its quarterly earnings results on Wednesday, April, 27th. The pharmaceutical company reported $0.88 earnings per share (E...
How often does GSK pay dividends? What is the dividend yield for GSK?
GSK announced a quarterly dividend on Wednesday, May 4th. Stockholders of record on Friday, May 20th will be given a dividend of $0.3496 per share...
Is GSK a good dividend stock?
GSK(NYSE:GSK) pays an annual dividend of $1.37 per share and currently has a dividend yield of 3.18%. The dividend payout ratio of GSK is 49.46%. T...
Who are GSK's key executives?
GSK's management team includes the following people: Ms. Emma N. Walmsley , CEO & Director (Age 52, Pay $4.88M) Mr. Iain James Mackay , CFO & E...
Who are some of GSK's key competitors?
Some companies that are related to GSK include Eli Lilly and (LLY) , Pfizer (PFE) , Roche (RHHBY) , AbbVie (ABBV) , Merck & Co., Inc. (MRK) ,...
Should I buy or sell GlaxoSmithKline stock right now?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last twelve months. There are currently 1 sell rat...
What is GlaxoSmithKline's stock price forecast for 2022?
14 Wall Street analysts have issued 1 year target prices for GlaxoSmithKline's shares. Their forecasts range from GBX 1,400 to GBX 2,100. On averag...
How has GlaxoSmithKline's stock price performed in 2022?
GlaxoSmithKline's stock was trading at GBX 1,606.60 at the start of the year. Since then, GSK stock has increased by 8.1% and is now trading at GBX...
When is GlaxoSmithKline's next earnings date?
GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Glax...
How were GlaxoSmithKline's earnings last quarter?
GlaxoSmithKline plc (LON:GSK) released its quarterly earnings data on Wednesday, July, 29th. The company reported $56.90 earnings per share for the...
How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?
GlaxoSmithKline announced a dividend on Wednesday, April 27th. Stockholders of record on Thursday, May 19th will be given a dividend of GBX 14 per...
Is GlaxoSmithKline a good dividend stock?
GlaxoSmithKline(LON:GSK) pays an annual dividend of GBX 0.80 per share and currently has a dividend yield of 4.39%. GSK has a dividend yield higher...
Who are GlaxoSmithKline's key executives?
GlaxoSmithKline's management team includes the following people: Ms. Emma N. Walmsley , CEO & Director (Age 52, Pay $3.88M) Mr. Iain James Macka...
Who are some of GlaxoSmithKline's key competitors?
Some companies that are related to GlaxoSmithKline include AstraZeneca (AZN) , Bayer Aktiengesellschaft (BAYN) , Dechra Pharmaceuticals (DPH) ,...
What is MarketBeat community ratings?
What is the dividend payout ratio for GlaxoSmithKline?
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote “Outperform” if you believe GSK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
How much does GlaxoSmithKline make?
Based on earnings estimates, GlaxoSmithKline will have a dividend payout ratio of 69.23% next year. This indicates that GlaxoSmithKline will be able to sustain or increase its dividend. View GlaxoSmithKline's dividend history.
What is the GSK symbol?
GlaxoSmithKline has a market capitalization of $105.63 billion and generates $43.79 billion in revenue each year. The pharmaceutical company earns $7.38 billion in net income (profit) each year or $2.98 on an earnings per share basis.
How much is GSK stock worth in 2020?
GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."
What is the P/E ratio of GlaxoSmithKline?
GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GSK stock has decreased by 1.6% and is now trading at $39.23. View which stocks have been most impacted by COVID-19.
What is GlaxoSmithKline?
The P/E ratio of GlaxoSmithKline is 17.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.33.
What is MarketBeat community ratings?
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
What is the dividend payout ratio of GlaxoSmithKline?
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote “Outperform” if you believe GSK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
What is GlaxoSmithKline?
The dividend payout ratio of GlaxoSmithKline is 93.79%. Payout ratios above 75% are not desirable because they may not be sustainable.
What is the P/E ratio of GlaxoSmithKline?
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc., and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Is GlaxoSmithKline a dividend payer?
The P/E ratio of GlaxoSmithKline is 17.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.41.
GSK settles Gilead dispute, rejects Unilever offer
GlaxoSmithKline is a leading dividend payer. It pays a dividend yield of 5.29%, putting its dividend yield in the top 25% of dividend-paying stocks.
GSK advances Covid-19 treatments
GSK has three main divisions, pharmaceuticals, vaccines and consumer healthcare. The company’s majority owned ViiV Healthcare subsidiary, a specialist HIV company, settled the case against Gilead Sciences (GILD) concerning its patents relating to dolutegravir, which is used with other medicines to treat HIV.
GlaxoSmithKline (GSK) stock forecast: How do analysts view the stock?
The pandemic disrupted immunisation programmes for other diseases in 2020 including shingles, for which GSK has a vaccine.
